Questo sito utilizza cookie tecnici e consente l'invio di cookie di "terze parti" al fine di effettuare misure di traffico per la valutazione delle prestazioni del sito. Per saperne di più, clicca sull'apposito bottone "Maggiori dettagli", che aprirà in modalità pop up l'informativa estesa, dove è possibile avere informazioni per negare il consenso all'installazione di qualunque cookie. Cliccando il bottone OK, o cliccando su una qualsiasi altra area del sito, presterai consenso all'uso dei cookie.

                                 

                                                                                                                                  NUOVO LABORATORIO FBTV 

Segnalazioni urgenze

dalle ore 16.30 alle ore 8.00

320 6132439

Segnalazione donazioni Multitessuto

dalle ore 8.00 alle ore 20.00

328 8606362

DONA IL 5X1000 
Sostieni la ricerca per il trapianto

Inserisci il Codice Fiscale 04478760269 
Come si fa

 

___________________________________________________________________________________________

Insieme per continuare a crescere e  migliorare le possibilità di cura      

 

 

In Evidenza In Evidenza

Indietro

2021 Pubblicazione Scientifica

2021 Pubblicazione Scientifica

Mirko Ragazzo. Matteo Val, Giulia Montagner, Diletta Trojan, Stefano Fusetti, Luca Guarda Nardini 19 April 2021

Human amniotic membrane: an improvement in the treatment of Medication-related osteonecrosis of the jaw

 

Cell Tissue Bank
https://doi.org/10.1007/s10561-021-09922-y(0123456789().,-volV() 0123458697().,-volV)

Abstract

The aim of this article is to report the results obtained by the use of HAM in surgical wound healing and the reduction of relapse in patients affected by Medication-related osteonecrosis of the jaw (MRONJ).The study involved patients with the diagnosis of MRONJ, surgically treated between October 2016 and April 2019, in a case–control setting. Enrolled patients were randomly divided into 2 groups. One group will be treated with resective surgery and with the insertion of HAM patch (Group A), while the second group had been treated exclusively with resective surgery (Group B).The patients underwent MRONJ surgical treatment with the placement of amniotic membrane patches at the wound site. Data regarding the long-term complications/functions were evaluated at 3, 6, 12, and 24 months after surgery. Pain measurements were performed before the intervention (T0), 7(T1) and 30(T2) days after surgery. 49 patients were included in the study. 2 patients of GROUP A after 30 days since they were surgically treated showed persistent bone exposure. 5 patients of group B demonstrated a lack of healing of the surgical wound with the persistence of bone exposed to 30 days after surgery. Statistical analysis ruled out any difference in OUTCOME (relapse) between GROUP A and B (p = 0.23). However, the Fisher test highlighted a significant difference between the use of HAM and only surgical treatment in pain at rest (p = 0.032). The use of amniotic membrane implement the patient's quality of life and reduce pain perception. has a learning curve that is fast enough to justify its routine use.

Download abstract